Email this article Withdrawal syndrome after tyrosine kinase inhibitors discontinuation in patients with chronic myeloid leukemia
- Authors: Chelysheva E.Y.1, Petrova A.N.1, Shukhov O.A.1, Bykova A.V.1, Nemchenko I.S.1, Gurianova M.A.1, Tsyba N.N.1, Turkina A.G.1
-
Affiliations:
- National Medical Research Center for Hematology
- Issue: Vol 94, No 7 (2022)
- Pages: 836-843
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/109734
- DOI: https://doi.org/10.26442/00403660.2022.07.201747
- ID: 109734
Cite item
Full Text
Abstract
Background. Withdrawal syndrome (WS) – a musculoskeletal pain after discontinuation of tyrosine kinase inhibitors (TKI) in patients with chronic myeloid leukemia (CML) – has been described in the treatment-free remission (TFR) studies. The pathophysiological mechanisms and predisposing factors of WS have not been well established.
Aim. Our aim was to evaluate clinical features and factors associated with WS in the Russian cohort of CML patients who discontinued TKI therapy.
Materials and methods. WS was evaluated in total of 183 CML patients with chronic phase and sustained deep molecular response (DMR). WS was defined as a musculoskeletal pain newly observed after TKI cessation or as a worsening of previously observed symptoms.
Results. DMR loss free survival at 36 months was 49% and 43% in prospective and retrospective groups respectively (p=0.96) with mеdian (Me) time of observation 33 months (range 1–136). WS was observed in 49 (27%) patients: grade 1–2 was in 45 (92%) patients, grade 3 – in 4 (8%) patients. Me time to WS occurrence was 2 months (range 1–7), Ме duration of WS was 5 months (range 1–35). WS was resolved in 14 of 15 patients with molecular relapse after 1–3 months of TKI re-initiation and was decreased in 1 patient. WS was completely resolved in 31 of 34 patients who continued remained in TFR and decreased in 3 patients. WS was resolved spontaneously or with nonsteroidal anti-inflammatory drugs in 14 (45%) and 17 (55%) patients accordingly. Older age (p<0.0001), longer duration of TKI therapy (p<0.0001) and presence of locomotion system diseases (p=0.022) were observed in patients with WS. No WS was observed in pregnant patients (р<0.001). Survival without DMR loss at 12 months after TKI stop was 66 and 42% in patients with and without WS accordingly (р=0.095).
Conclusion. The rate of WS was 27% that is in a good concordance with the data of the other TFR studies. A longer period of TKI exposure, older age and the history of locomotion system diseases were associated with the development of the WS. We found for the first time that WS was not observed in patients with pregnancy. There was no association of WS development and the rate of molecular relapses.
Full Text
##article.viewOnOriginalSite##About the authors
Ekaterina Yu. Chelysheva
National Medical Research Center for Hematology
Email: ap996@mail.ru
ORCID iD: 0000-0001-6423-1789
д-р мед. наук, вед. науч. сотр. отд. диагностики и лечения гематологических заболеваний
Russian Federation, MoscowAnna N. Petrova
National Medical Research Center for Hematology
Author for correspondence.
Email: ap996@mail.ru
ORCID iD: 0000-0001-5730-2593
канд. мед. наук, науч. сотр. отд. диагностики и лечения гематологических заболеваний
Russian Federation, MoscowOleg A. Shukhov
National Medical Research Center for Hematology
Email: ap996@mail.ru
ORCID iD: 0000-0001-5393-0816
канд. мед. наук, ст. науч. сотр. отд. диагностики и лечения гематологических заболеваний
Russian Federation, MoscowAnastasiia V. Bykova
National Medical Research Center for Hematology
Email: ap996@mail.ru
ORCID iD: 0000-0002-3123-8316
врач-гематолог клинико-диагностического отд-ния гематологии миелопролиферативных заболеваний
Russian Federation, MoscowIrina S. Nemchenko
National Medical Research Center for Hematology
Email: ap996@mail.ru
ORCID iD: 0000-0001-9178-1428
канд. мед. наук, науч. сотр. отд. диагностики и лечения гематологических заболеваний
Russian Federation, MoscowMargarita A. Gurianova
National Medical Research Center for Hematology
Email: ap996@mail.ru
ORCID iD: 0000-0001-9984-389X
врач-гематолог отд-ния химиотерапии гематологических заболеваний
Russian Federation, MoscowNikolay N. Tsyba
National Medical Research Center for Hematology
Email: ap996@mail.ru
ORCID iD: 0000-0001-7816-808X
д-р мед. наук, аналитик отд. диагностики и лечения гематологических заболеваний
Russian Federation, MoscowAnna G. Turkina
National Medical Research Center for Hematology
Email: ap996@mail.ru
ORCID iD: 0000-0001-9947-2371
д-р мед. наук, проф., зав. клинико- диагностическим отд-нием гематологии миелопролиферативных заболеваний, вед. науч. сотр. отд. диагностики и лечения гематологических заболеваний
Russian Federation, MoscowReferences
- Sasaki K, Strom SS, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2(5):e186-93. doi: 10.1016/S2352-3026(15)00048-4
- Bower H, Björkholm M, Dickman PW, et al. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016;34(24):2851-7. doi: 10.1200/jco.2015.66.2866
- Туркина А.Г., Новицкая Н.В., Голенков А.К., и др. Регистр больных хроническим миелолейкозом в Российской Федерации: от наблюдательного исследования к оценке эффективности терапии в клинической практике. Клиническая онкогематология. 2017;10(3):390-401 [Turkina AG, Novickaja NV, Golenkov AK, et al. Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice. Clinical Oncohematology. 2017;10(3):390-401 (in Russian)]. doi: 10.21320/2500-2139-2017-10-3-390-401
- Mahon F, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3
- Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515-22. doi: 10.1182/blood-2013-02-483750
- Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-57. doi: 10.1016/s1470-2045(18)30192-x
- Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525-31. doi: 10.1038/leu.2017.63
- Mahon FX, Boquimpani C, Kim DW, et al. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Ann Intern Med. 2018;168(7):461-70. doi: 10.7326/m17-1094
- Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528-35. doi: 10.1016/s2352-3026(15)00196-9
- Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846-54. doi: 10.1182/blood-2016-09-742205
- Туркина А.Г., Петрова А.Н., Челышева Е.Ю., и др. Результаты проспективного исследования по наблюдению больных хроническим миелолейкозом после прекращения терапии ингибиторами тирозинкиназ. Гематология и трансфузиология. 2020;65(4):370-85 [Turkina AG, Petrova AN, Chelysheva EYu, et al. A prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy. Russian Journal of Hematology and Transfusiology. 2020;65(4):370-85 (in Russian)]. doi: 10.35754/0234-5730-2020-65-4-370-385
- Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128(1):17-23. doi: 10.1182/blood-2016-01-694265
- Laneuville P. When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Curr Treat Options Oncol. 2018;19(3):15. doi: 10.1007/s11864-018-0532-2
- Rea D, Cayuela JM. Treatment-free remission in patients with chronic myeloid leukemia. Int J Hematol. 2018;108(4):355-64. doi: 10.1007/s12185-017-2295-0
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-84. doi: 10.1038/s41375-020-0776-2
- Chen KK, Du TF, Xiong PS, et al. Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis. Front Oncol. 2019;9:372. doi: 10.3389/fonc.2019.00372
- Park JS, Lee SE, Jeong SH, et al. Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. Leuk Lymphoma. 2016;57(2):341-7. doi: 10.3109/10428194.2015.1049166
- Kota V, Atallah E. Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. Clin Lymphoma Myeloma Leuk. 2019;19(8):480-7. doi: 10.1016/j.clml.2019.05.007
- Richter J, Söderlund S, Lübking A, et al. Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome? J Clin Oncol. 2014;32(25):2821-3. doi: 10.1200/jco.2014.55.6910
- Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101(6):717-23. doi: 10.3324/haematol.2015.139899
- Katagiri S, Tauchi T, Ando K, et al. Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia. Leuk Res Rep. 2017;7:33-5. doi: 10.1016/j.lrr.2017.04.002
- Berger MG, Pereira B, Rousselot P, et al. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Br J Haematol. 2019;187(3):337-46. doi: 10.1111/bjh.16083
- Shah NP, García-Gutiérrez V, Jiménez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2019;61(3):650-9. doi: 10.1080/10428194.2019.1675879
- Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295(1):139-45.
- Galimberti S, Fontanelli G, Barsotti S, et al. Increased values of the circulating PDGFβ sustains the "withdrawal syndrome" after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia. Blood Cells Mol Dis. 2015;55(3):211-2. doi: 10.1016/j.bcmd.2015.06.010
- Takahashi N, Nishiwaki K, Nakaseko C, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103(11):1835-42. doi: 10.3324/haematol.2018.194894
- Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0, 2009. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed: 11.07.2022.
- Petinati NA, Petrova AN, Chelysheva EY, et al. Multipotent Mesenchymal Stromal Cells in Patients with Chronic Myeloid Leukemia before Discontinuation of Tyrosine Kinase Inhibitors. Bull Exp Biol Med. 2019;167(4):580-3. doi: 10.1007/s10517-019-04575-0
- Petrova A, Chelysheva E, Shukhov O, et al. Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI. Clin Lymphoma Myeloma Leuk. 2020;20(5):267-71. doi: 10.1016/j.clml.2019.12.019
- Radich JP, Deininger M, Abboud CN, et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(9):1108-35. doi: 10.6004/jnccn.2018.0071
- Рубрикатор клинических рекомендаций. Режим доступа: http://cr.rosminzdrav.ru/#!/recomend/120. Ссылка активна на 11.07.2022 [Rubrikator klinicheskikh rekomendatsii. Available at: http://cr.rosminzdrav.ru/#!/recomend/120. Accessed: 11.07.2022 (in Russian)].
Supplementary files
